Method
Level · gp.fundamentals.debt_to_revenue
Raw value 765.69% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTNuvation Bio Inc.'s latest supported as-filed period reports revenue of $31.7M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 765.69% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -135.60% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 555.64% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 62.80% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -161.06% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 96.76% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +4.3% from the comparable as-filed period.
Debt changed +416.5% from the comparable as-filed period.
Inventory changed +3505.3% from the comparable as-filed period.
Net income changed -6.5% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
NUVB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001521111-26-000005SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-336751SEC ↗10-QAug 6, 2026Period Jun 30, 20260001193125-26-336646SEC ↗4Jul 17, 2026Period Jul 15, 20260002039891-26-000008SEC ↗8-KJul 6, 2026Period Jun 30, 20260001193125-26-296398SEC ↗8-KJun 30, 2026Period Jun 24, 20260001193125-26-290823SEC ↗4Jun 24, 2026Period Jun 23, 20260001734780-26-000004SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 19, 2026Filed Aug 21, 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option ExerciseDirect | 100,000 | $2 | $187,000 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Open Market SaleDirect | 100,000 | $7 | $709,240 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option ExerciseDirect | 100,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 33.01% · OPTIONAL
Operating income changed +19.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating margin changed +115466 basis points from the comparable as-filed period.
Research & development changed +12.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001369453-26-000008